Despite the fact that greater than 75% of MM tumour samples overexpressed EGFR, clinical trials targeting EGFR in MM with tyrosine kinase inhibitors have yielded some objective responses, but not with the desired frequency (Govindan et al, 2005; Garland et al, 2007). The gene discussed is EGFR; the disease is neoplasm.